Welcome to our dedicated page for BioAge Labs news (Ticker: BIOA), a resource for investors and traders seeking the latest updates and insights on BioAge Labs stock.
BioAge Labs, Inc. develops clinical-stage biopharmaceutical candidates for cardiometabolic diseases by targeting the biology of human aging. Its news centers on BGE-102, a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases, including diabetic macular edema.
Recurring updates cover Phase 1 biomarker and tolerability data, indication development for inflammation-driven disease, and research into long-acting injectable and oral small-molecule APJ agonists for obesity. BioAge also reports financial results, public offerings, R&D presentations, and collaborations that use its human longevity data platform to identify metabolic-aging pathways.
On January 16, 2023, BioArctic AB announced that its partner, Eisai, has submitted a marketing authorization application for lecanemab (brand name: LEQEMBI™) for early Alzheimer's disease treatment in Japan. The application follows Phase 3 Clarity AD study results, showing significant clinical decline reduction. BioArctic is entitled to a milestone payment of MEUR 5 upon acceptance by the PMDA. The FDA granted accelerated approval for lecanemab on January 6, 2023, with a supplemental application for full approval submitted on the same date. Eisai manages global development, while BioArctic prepares for commercialization in the Nordics.